Susquehanna International Group, LLP Purple Biotech Ltd. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	BUY	$1.38 - $2.05 $2,208 - $3,279	1,600 Added 5.48%	30,800 $43,000
Q1 2023 May 16, 2023	SELL	$1.36 - $2.3 $147,288 - $249,089	-108,300 Reduced 78.76%	29,200 $52,000
Q4 2022 Feb 14, 2023	BUY	$1.38 - $2.22 $52,577 - $84,582	38,100 Added 38.33%	137,500 $189,000
Q3 2022 Nov 14, 2022	BUY	$1.9 - $2.69 $84,930 - $120,243	44,700 Added 81.72%	99,400 $202,000
Q2 2022 Aug 15, 2022	BUY	$2.39 - $4.15 $14,101 - $24,485	5,900 Added 12.09%	54,700 $131,000
Q1 2022 May 16, 2022	SELL	$2.45 - $4.3 $43,365 - $76,110	-17,700 Reduced 26.62%	48,800 $194,000
Q4 2021 Feb 14, 2022	SELL	$3.75 - $4.67 $449,625 - $559,933	-119,900 Reduced 64.32%	66,500 $259,000
Q3 2021 Nov 15, 2021	SELL	$4.4 - $5.59 $335,280 - $425,958	-76,200 Reduced 29.02%	186,400 $850,000
Q2 2021 Aug 11, 2021	BUY	$3.75 - $6.72 $569,250 - $1.02 Million	151,800 Added 137.0%	262,600 $1.28 Million
Q1 2021 May 17, 2021	BUY	$3.93 - $6.99 $435,444 - $774,492	110,800 New	110,800 $458,000

Ticker PPBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,303,300
Market Cap $67M
Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.